0.65Open0.65Pre Close0 Volume2 Open Interest7.50Strike Price0.00Turnover195.56%IV-18.82%PremiumMay 16, 2025Expiry Date2.54Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8125Delta0.0609Gamma3.21Leverage Ratio-0.0330Theta0.0026Rho2.61Eff Leverage0.0061Vega
TYRA BIOSCIENCES, INC. Stock Discussion
Tyra Bio Achieves 54.5% Response Rate in Cancer Trial, Secures 3-Year Runway
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$